In This Article:
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently approved by the FDA, which was widely expected, but the initial daily price of $31 is a bit above the threshold of $8 per day the firm’s key opinion leaders cites as the limit to ensure broad uptake, the analyst tells investors. Journavx’s value proposition as an opioid alternative, however, should not be ignore and could still drive uptake in acute pain.
Invest with Confidence:
-
Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
-
Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
-
Vertex Pharmaceuticals price target raised to $550 from $535 at H.C. Wainwright
-
Vertex Pharmaceuticals price target lowered to $320 from $325 at Baird
-
Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays
-
Vertex Pharmaceuticals announces Casgevy reimbursement pact with NHS England
-
Vertex (VRTX) Secures FDA Approval for Highly-Awaited Non-Opioid Painkiller